Walder Wyss has acted as advisor to Sleepiz in the completion of its CHF 4.4 million Series A financing round. The newly raised capital will support Sleepiz expansion of its portfolio to chronic respiratory disease monitoring.
Norres, a portfolio company of Triton Smaller Mid-Cap Fund I, acquired the Baggerman Group. The parties have agreed not to disclose the purchase price. The Baggerman Group, headquartered in Roermond, Netherlands, is a specialist
CMS Switzerland welcomed Vaïk Müller (pictured) as a partner of the firm. In his new role, Müller will help develop the firm’s expertise in areas of banking & finance along with
Gxo Logistics, a global provider of transportation and logistics solutions, has appointed Maria Elena Scolaro (pictured) as head of legal affairs for Italy and Switzerland. Scolaro is reporting to general counsel for Europe and to
The city of Sierre, the association of the municipalities of the District of Sierre and TechnoArk acquired a majority stake in the Techno-Pôle of Sierre. Python acted as counsel to the buyers. Python team
Maus Frères and Coop-Group cooperative announced the sale of all shares of Jumbo-Markt, a Swiss do-it-yourself store operator, for an undisclosed consideration. Following merger control clearance by the Swiss Competition Commission the transaction has
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
La Mobilière, TX Group, Ringier and General Atlantic form a joint venture to create a digital marketplace group. The CEO of the joint venture will be Gilles Despas, currently CEO of the Scout24 Switzerland
VectivBio Holding, clinical-stage biopharmaceutical company specialising in novel transformational treatments for severe rare conditions announced the acquisition of Comet Therapeutics, a biotechnology company that has been developing drugs to address previously untreatable inherited metabolic diseases.
HBM Healthcare Investments successfully issued CHF 100 million 1.125 per cent Bonds due 2027. The bonds will be admitted for trading and listing on the SIX Swiss Exchange. The advisors Homburger acted as counsel to HBM Healthcare
